PuSH - Publikationsserver des Helmholtz Zentrums München

Ulrich, A.* ; Weitz, J.* ; Büchler, M.W.*

Strahlentherapie bei Rektumkarzinom.

Rectal cancer. How much radiotherapy do surgery patients need?.

Chirurg 80, 266-273 (2009)
DOI Verlagsversion bestellen
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
With the introduction of total mesorectal excision in rectal cancer treatment, local recurrence rates could be reduced below 10%. Previously such results could be achieved only in combination with multimodal therapy. Therefore the role of multimodal therapy had to be redefined. Randomized controlled trials have shown that the local recurrence rate can be reduced with no effect on overall survival and that neoadjuvant radiotherapy is superior to adjuvant radiotherapy. Controversy exists however about the best way of application, as either short-course radiotherapy (5x5 Gy) or combined radiochemotherapy, but not about its necessity, especially considering recent reports about late side effects of radiotherapy. It was the aim of this paper to explore the literature for the amount of radiotherapy surgical patients for rectal cancer really need. Interestingly, those with high rectal tumors do not benefit from radiotherapy. Further randomized trials are however required to address the need of radiotherapy in UICC tumor stages II or III with negative circumferential margin.
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
ISSN (print) / ISBN 0009-4722
Quellenangaben Band: 80, Heft: 4, Seiten: 266-273 Artikelnummer: , Supplement: ,
Verlag Berufsverband der Deutschen Chirurgen
Institut(e) Institute for Pancreatic Beta Cell Research (IPI)